Lumiere Therapeutics

Lumiere Therapeutics is a pre-clinical stage biotechnology company focused on the development of light-activated prodrugs for the treatment of solid tumors. Spun out of the University of North Carolina at Chapel Hill, the company's proprietary platform utilizes specific wavelengths of light to trigger the release of potent therapeutic agents directly at the site of the disease. This approach is designed to maximize therapeutic efficacy while significantly reducing the systemic toxicity and off-target effects associated with traditional chemotherapy. The company's technology is versatile, allowing for the precise spatial and temporal control of various therapeutic payloads within the tumor microenvironment.